Cash, Cash Equivalents, and Short-term Investments of MERRIMACK PHARMACEUTICALS INC from 30 Jun 2012 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
Summary
MERRIMACK PHARMACEUTICALS INC quarterly Cash, Cash Equivalents, and Short-term Investments in USD history and change rate from 30 Jun 2012 to 31 Mar 2024.
  • MERRIMACK PHARMACEUTICALS INC Cash, Cash Equivalents, and Short-term Investments for the quarter ending 31 Mar 2024 was $244,100,000, a 1158% increase year-over-year.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, and Short-term Investments, Quarterly (USD)
Cash, Cash Equivalents, and Short-term Investments, YoY Quarterly Change (%)

MERRIMACK PHARMACEUTICALS INC Quarterly Cash, Cash Equivalents, and Short-term Investments (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $244,100,000 +$224,700,000 +1158% 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $18,900,000 -$500,000 -2.6% 31 Dec 2023 10-K 07 Mar 2024 2023 FY
Q3 2023 $18,900,000 +$5,800,000 +44% 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $19,000,000 +$5,600,000 +42% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $19,400,000 +$5,100,000 +36% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $19,400,000 +$5,200,000 +37% 31 Dec 2022 10-K 09 Mar 2023 2022 FY
Q3 2022 $13,100,000 -$1,500,000 -10% 30 Sep 2022 10-Q 03 Nov 2022 2022 Q3
Q2 2022 $13,400,000 -$1,500,000 -10% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 $14,300,000 +$400,000 +2.9% 31 Mar 2022 10-Q 05 May 2022 2022 Q1
Q4 2021 $14,200,000 +$200,000 +1.4% 31 Dec 2021 10-K 09 Mar 2022 2021 FY
Q3 2021 $14,600,000 -$1,200,000 -7.6% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $14,900,000 -$800,000 -5.1% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $13,900,000 -$4,100,000 -23% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $14,000,000 -$2,600,000 -16% 31 Dec 2020 10-K 10 Mar 2021 2020 FY
Q3 2020 $15,800,000 30 Sep 2020 10-Q 04 Nov 2020 2020 Q3
Q2 2020 $15,700,000 -$24,200,000 -61% 30 Jun 2020 10-Q 07 Aug 2020 2020 Q2
Q1 2020 $18,000,000 -$40,500,000 -69% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $16,600,000 -$54,700,000 -77% 31 Dec 2019 10-K 12 Mar 2020 2019 FY
Q2 2019 $39,900,000 -$20,100,000 -34% 30 Jun 2019 10-Q 17 Jul 2019 2019 Q2
Q1 2019 $58,500,000 -$17,800,000 -23% 31 Mar 2019 10-Q 10 May 2019 2019 Q1
Q4 2018 $71,300,000 31 Dec 2018 10-K 06 Mar 2019 2018 FY
Q3 2018 $84,800,000 30 Sep 2018 10-Q 07 Nov 2018 2018 Q3
Q2 2018 $60,000,000 30 Jun 2018 10-Q 07 Aug 2018 2018 Q2
Q1 2018 $76,300,000 31 Mar 2018 10-Q 08 May 2018 2018 Q1
Q3 2014 $153,700,000 -$28,800,000 -16% 30 Sep 2014 10-Q 10 Nov 2014 2014 Q3
Q2 2014 $92,700,000 +$30,600,000 +49% 30 Jun 2014 10-Q 11 Aug 2014 2014 Q2
Q1 2014 $124,200,000 +$37,500,000 +43% 31 Mar 2014 10-Q 06 May 2014 2014 Q1
Q4 2013 $155,200,000 31 Dec 2013 10-K 04 Mar 2014 2013 FY
Q3 2013 $182,500,000 +$95,800,000 +110% 30 Sep 2013 10-Q 08 Nov 2013 2013 Q3
Q2 2013 $62,100,000 -$44,600,000 -42% 30 Jun 2013 10-Q 08 Aug 2013 2013 Q2
Q1 2013 $86,700,000 31 Mar 2013 10-Q 13 May 2013 2013 Q1
Q3 2012 $86,700,000 30 Sep 2012 10-Q 14 Nov 2012 2012 Q3
Q2 2012 $106,700,000 30 Jun 2012 10-Q 14 Aug 2012 2012 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.